In 1998, I was diagnosed with metastatic melanoma and given months to live. I consulted more than a dozen leading oncologists and got conflicting recommendations. No one could tell me: ‘Which treatment is best for me?’

A clinical trial saved my life—despite itself being unsuccessful—only raising more questions. Why did this therapy work for me but not for others? Could my experience help similar patients? It was life-saving knowledge I wanted to share with all cancer patients.

Welcome to Cancer Commons.

Marty Tenenbaum, PhD Founder of Cancer Commons

Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.

  • The group was useful, but Cancer Commons definitely sets itself apart. To have validation from experts who truly cared and spent time with me talking through all the options was just amazing. I didn’t feel rushed, and the review of my dad’s case was so thorough. Matt met us where we were at.

    Megan Anz

  • My experience with Cancer Commons has been fantastic! Their support and advice have been extremely helpful. I will always be very greatful to the Cancer Commons team. They took the time to contact me by phone to learn more about my diagnosis so they could study my case and recommend options to consider. Thanks so much to all the people involved.

    Michael Goold
    Grade 4 glioblastoma patient

  • Precision oncology is very complicated and changes every day. The scientists of Cancer Commons provide rapid, compassionate, scientifically sound information about best options, a remarkable free service.

    Razelle Kurzrock, MD
    U.C. San Diego, CureMatch, Inc.

  • Cancer Commons walked with us as we faced treatment decisions following my husband’s latest recurrence of glioblastoma. Matthew’s expertise helped us sort through information during an overwhelming time. And Lauren’s concern made us feel cared for.

    Ellie
    Wife of a glioblastoma patient
  • Cancer Commons is truly unique at rapidly matching patients with advanced cancer with the best precision therapy or clinical trial.

    E. David Crawford, MD
    Cancer Commons Advisor

Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.